CCO Oncology Podcast
By Clinical Care Options
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Clinical Care Options
Category: Courses
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 6
Reviews: 0
Episodes: 168
Description
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
| Episode | Date |
|---|---|
|
Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer
|
Mar 28, 2024 |
|
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer
|
Mar 18, 2024 |
|
Current Considerations for Adverse Event Management With HER3-Directed Agents
|
Dec 26, 2023 |
|
Unpacking the Potential of HER3-Targeted Therapy in NSCLC
|
Dec 26, 2023 |
|
Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer
|
Dec 26, 2023 |
|
Expert Insight on Seminal New Clinical Trial Data Presented at the 2023 IGCS Conference Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
|
Dec 04, 2023 |
|
Novel Emerging Investigational Treatment Strategies for Patients With Myelofibrosis
|
Nov 30, 2023 |
|
A Year in Review and a Look to the Future: BTKi in CLL and MCL
|
Nov 20, 2023 |
|
Expert Insight on Key Updates and New Clinical Trial Data From the ESMO 2023 Congress Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
|
Nov 17, 2023 |
|
Expert Insights and Considerations for Precision Care With HER3-Targeted Agents in NSCLC and Breast Cancer
|
Nov 07, 2023 |
|
Improving Care for Black Patients With Endometrial Cancer
|
Nov 06, 2023 |
|
Expert Insight on Key Updates and New Clinical Trial Data From the ESGO 2023 Congress Informing Treatment for Cervical, Ovarian, and Endometrial Cancers
|
Oct 13, 2023 |
|
New Evidence With BTK Inhibitor Therapy in CLL and MCL From SOHO 2023
|
Oct 04, 2023 |
|
New Evidence With BTK Inhibitor Therapy in MCL From ICML 2023
|
Aug 17, 2023 |
|
New Evidence With BTK Inhibitor Therapy in CLL From EHA 2023
|
Jul 28, 2023 |
|
Expert Insight on Key Updates and New Clinical Trial Data From the 2023 ASCO Annual Meeting, Informing Treatment for Cervical, Ovarian, and Endometrial Cancers
|
Jun 22, 2023 |
|
Expert Insight on New Data From SGO 2023 Informing Treatment for Endometrial, Cervical, and Ovarian Cancers
|
May 04, 2023 |
|
Practical Insights on Using BCMA-Targeted Therapies in Multiple Myeloma
|
Apr 26, 2023 |
|
Contemporary Approaches to Treating Myelofibrosis: A Conversation Between Experts
|
Apr 11, 2023 |
|
BRCA Testing and Adjuvant Therapy in Early Breast Cancer: Experiences and Challenges
|
Apr 05, 2023 |
|
Experts Discuss Claudin 18.2: A New Target for Precision Care of Gastric and Gastroesophageal Cancers
|
Mar 28, 2023 |
|
Treatment Considerations for Patients With Essential Thrombocythemia: A Conversation Between Experts
|
Feb 23, 2023 |
|
FAQs on the Use of Asparaginase Therapy in Young and Older Adults With Acute Lymphoblastic Leukemia
|
Feb 20, 2023 |
|
Experts Answer Questions on the Management of Patients With T-Cell Lymphomas
|
Feb 17, 2023 |
|
Experts Answer Questions on Personalized Management of Patients With Myelodysplastic Syndromes
|
Feb 17, 2023 |
|
Individualizing Care for Patients With Triple-Negative Breast Cancer
|
Jan 18, 2023 |
|
Contemporary Approaches to Treating Polycythemia Vera: A Conversation Between Experts
|
Jan 11, 2023 |
|
HCC Surveillance: Challenges and Opportunities
|
Jan 03, 2023 |
|
A Patient’s Perspective on Effective Communication With the Healthcare Team: My Journey With High-Risk HR-Positive/HER2-Negative Early Breast Cancer
|
Dec 13, 2022 |
|
The Transgender Cancer Experience: A Conversation Between an Oncologist and a Transmasculine Individual on Navigating the Healthcare System
|
Nov 29, 2022 |
|
Expert Thoughts on Studies of Interest Presented at the 2022 ESGO Annual Meeting on Gynecologic Cancers
|
Nov 29, 2022 |
|
Evolving Role of BTK Inhibitors in CLL: Experts Answer Your Questions
|
Nov 09, 2022 |
|
New Evidence With BTK Inhibitor Therapy in CLL and MCL From the SOHO 2022 Annual Meeting
|
Oct 28, 2022 |
|
Expert Thoughts on Key Trials of Interest for Ovarian and Cervical Cancer at the IGCS 2022 Annual Global Meeting
|
Oct 24, 2022 |
|
Relapsed/Refractory Myeloma: Navigating the Complex Treatment Landscape
|
Oct 24, 2022 |
|
Expert Insights on Key Updates From the 2022 ESMO Congress on PARP Inhibitors in Ovarian Cancer
|
Oct 04, 2022 |
|
Managing EGFR-Mutated Non-Small-Cell Lung Cancer in Today’s Clinic: Expert Answers to Frequently Asked Questions
|
Sep 28, 2022 |
|
New Evidence With BTK Inhibitor Therapy in CLL and MCL From the Pan Pacific Lymphoma Conference 2022
|
Aug 30, 2022 |
|
Experts Discuss Challenges in Advanced Hepatocellular Carcinoma Management
|
Aug 22, 2022 |
|
HER2-Positive Breast Cancer: Current Approaches for Quality Care
|
Jul 28, 2022 |
|
New Evidence With BTK Inhibitor Therapy in CLL and MCL From EHA 2022
|
Jul 21, 2022 |
|
New Evidence With BTK Inhibitor Therapy in CLL and MCL From ASCO 2022
|
Jul 06, 2022 |
|
Expert Insights on New Data From ASCO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
|
Jun 30, 2022 |
|
Expert Insight on Key Data From SGO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
|
May 19, 2022 |
|
Call to Action and Reflection: Inclusive, Compassionate, and High-Quality Healthcare for Transgender Individuals
|
May 13, 2022 |
|
Inclusive Healthcare for Transgender Individuals: Insights From a Healthcare Professional’s Transition Experience
|
May 02, 2022 |
|
Anti-TIGIT Therapy: Overview of Current Clinical Evidence and Key Ongoing Trials
|
Apr 15, 2022 |
|
Targeting TIGIT: Understanding New Approaches for Inhibiting the Immune Checkpoint Pathway
|
Apr 07, 2022 |
|
Evolving Treatment Landscape With Regorafenib and TAS-102 in Metastatic Colorectal Cancer
|
Apr 06, 2022 |
|
Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL
|
Mar 31, 2022 |
|
Expert Insights on Optimal Current Management of Patients With Cholangiocarcinoma
|
Mar 21, 2022 |
|
Cancer Conversations: 3 Case Challenges of Real Patients With Myelodysplastic Syndromes
|
Mar 14, 2022 |
|
Expert Insights on Targeted Therapies for Advanced Systemic Mastocytosis
|
Mar 10, 2022 |
|
Advances in B-Cell Lymphomas: Understanding Current Treatment Approaches
|
Feb 25, 2022 |
|
TKIs for Advanced HCC in the Second Line and Beyond
|
Feb 22, 2022 |
|
New Directions With PARP Inhibitors in Pancreatic Cancer
|
Feb 21, 2022 |
|
Evolving Therapy for Myeloma: Experts Discuss Patient Case Examples
|
Feb 18, 2022 |
|
Expert Insights on Advances in Immune Thrombocytopenia
|
Feb 07, 2022 |
|
Precision Medicine for aTTP: Expert Answers to Your Questions
|
Feb 01, 2022 |
|
Precision Medicine for T-Cell Lymphomas: Expert Answers to Your Questions
|
Jan 31, 2022 |
|
Multidisciplinary Overview of EGFR-Mutated NSCLC: An Expert Panel Discussion From Biomarker Testing to Managing Progressive Disease
|
Jan 26, 2022 |
|
Experts Answer Questions on Current and Emerging Options for Hemophilia A Management
|
Jan 14, 2022 |
|
Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations
|
Jan 10, 2022 |
|
Induction and Maintenance Therapy for Fit Patients With AML Without Targetable Mutations
|
Jan 10, 2022 |
|
Strategies for Secondary AML and Emerging Therapies for AML
|
Jan 10, 2022 |
|
An Overview of AML and Treatment Strategies for Patients Unfit for Intensive Therapy
|
Jan 10, 2022 |
|
Managing Higher-Risk and Relapsed/Refractory Myelodysplastic Syndromes: Nursing Implications
|
Dec 22, 2021 |
|
Managing Lower-Risk Myelodysplastic Syndrome: Nursing Implications
|
Dec 22, 2021 |
|
Key Factors Influencing Later-Line Treatment Selection for Patients With Metastatic Colorectal Cancer
|
Dec 17, 2021 |
|
The Evolving Role of TKIs in First-line Treatment of Advanced HCC
|
Dec 14, 2021 |
|
Expert Insight on Important Clinical Trial Data From ESGO 2021 Informing Treatment for Ovarian Cancer and Endometrial Cancers
|
Nov 23, 2021 |
|
Experts Answer FAQs on Immunotherapy for Non-Small-Cell Lung Cancer
|
Nov 23, 2021 |
|
Overcoming Acquired Resistance With Second-Generation TRK Inhibitors
|
Nov 09, 2021 |
|
Role of TKIs in Nonadipocytic Soft Tissue Sarcoma and Advanced Osteosarcoma
|
Nov 02, 2021 |
|
PARP Inhibitors in Pancreatic Cancer: Experts Discuss Importance of Testing for Biomarkers Along With Current Treatment Landscape
|
Oct 26, 2021 |
|
Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
|
Oct 21, 2021 |
|
First-Generation TRK Inhibitors: Clinical Evidence and Indications
|
Oct 15, 2021 |
|
PARP Inhibitors in Ovarian Cancer: Experts Discuss Patient Cases and the Current Paradigm
|
Oct 14, 2021 |
|
Counseling Patients and Caregivers on Prophylaxis Therapy for Severe Hemophilia A
|
Oct 08, 2021 |
|
Rationale for NTRK Testing in Patients With Cancer
|
Oct 08, 2021 |
|
Expert Answers to HCP Questions on Androgen Deprivation Therapy for Prostate Cancer
|
Oct 07, 2021 |
|
Expert Insight on Important Clinical Trial Data From ESMO 2021 Informing Treatment for Endometrial and Ovarian Cancer
|
Sep 29, 2021 |
|
Expert Insight on New Evidence Poised to Change the Treatment Landscape in Melanoma
|
Sep 28, 2021 |
|
Expert Insight on Practice Changing From IGCS 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer
|
Sep 21, 2021 |
|
Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address FAQs
|
Aug 24, 2021 |
|
Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer
|
Aug 19, 2021 |
|
Essential Biomarker Testing in GI Cancers
|
Aug 18, 2021 |
|
CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions
|
Aug 05, 2021 |
|
The Latest Advances and Guidance in Nonmetastatic Castration-Resistant Prostate Cancer
|
Jul 30, 2021 |
|
Managing Serious Adverse Events Associated with BTK Inhibitor Treatment
|
Jul 27, 2021 |
|
Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 2: Patient Strategies for Self-Management
|
Jul 27, 2021 |
|
Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 1: Drug–Drug and Drug–Food Interactions
|
Jul 27, 2021 |
|
BTK Inhibitors in CLL and Lymphomas: Overview and Current Indications
|
Jul 23, 2021 |
|
Adverse Events Associated with BTK Inhibitor Treatment
|
Jul 23, 2021 |
|
Radiopharmaceuticals in the Treatment of Metastatic Castration-Resistant Prostate Cancer
|
Jul 20, 2021 |
|
Expert Answers to HCP Questions on CAR T-Cell Therapy
|
Jul 19, 2021 |
|
How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on BCMA-Targeted Therapies
|
Jul 19, 2021 |
|
How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on Selinexor, Venetoclax, and Melphalan Flufenamide
|
Jul 16, 2021 |
|
Treatment Options for Patients With Multiple Myeloma After First Relapse
|
Jul 14, 2021 |
|
Caring for Patients With Newly Diagnosed Multiple Myeloma
|
Jul 14, 2021 |
|
Precision Medicine in Gynecologic Cancers: Expert Answers to Your Questions
|
Jul 12, 2021 |
|
Expert Answers to Questions on Managing Neurofibromatosis Type 1 and MEK Inhibitors for NF1-Associated Plexiform Neurofibromas
|
Jul 12, 2021 |
|
Expert Answers to Questions on PARP Inhibitor Combinations in Prostate Cancer
|
Jun 30, 2021 |
|
Immunotherapy for Advanced HCC: Current Options and Expert Answers to Clinician Questions
|
Jun 29, 2021 |
|
Expert Insight on Key Data From ASCO 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer
|
Jun 24, 2021 |
|
Optimizing Therapy for Relapsed/Refractory Multiple Myeloma: Expert Answers to Your Questions
|
Jun 17, 2021 |
|
Experts Answer FAQs on Biomarker-Driven Therapy for Non-Small-Cell Lung Cancer
|
May 19, 2021 |
|
Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC
|
May 18, 2021 |
|
Immunotherapy for Advanced HCC: Case Series
|
May 17, 2021 |
|
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Germany
|
May 13, 2021 |
|
Managing Toxicities Associated With FGFR Inhibitors in Urothelial Cancer and Beyond
|
May 04, 2021 |
|
Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
|
Apr 28, 2021 |
|
Expert Answers to Questions on Contemporary Management of Multiple Myeloma
|
Apr 22, 2021 |
|
Combining PARP inhibitors With Other Treatments for Men With Prostate Cancer: Clinical Trial Updates
|
Apr 19, 2021 |
|
Rationale for Combining PARP Inhibitors With Other Therapies in Prostate Cancer
|
Apr 15, 2021 |
|
Expert Insight on Key Data From SGO 2021 Informing Treatment for Endometrial and Ovarian Cancer
|
Apr 06, 2021 |
|
Expert Answers to Questions on PARP Inhibition for Prostate Cancer
|
Apr 06, 2021 |
|
Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL
|
Mar 26, 2021 |
|
Improving Outcomes in EGFR-Mutated Non-Small-Cell Lung Cancer: Global Insights on Evolving Practice Standards
|
Mar 25, 2021 |
|
Targeting FGFR in Urothelial Cancer and Beyond
|
Mar 23, 2021 |
|
Expert Answers to HCP Questions on Pancreatic Cancer Treatment
|
Mar 22, 2021 |
|
Expert Answers to HCP Questions on CAR T-Cell Therapies in Lymphoma
|
Mar 18, 2021 |
|
Frequently Asked Questions on Emerging Antibody–Drug Conjugates in the Treatment of Advanced Non-Small-Cell Lung Cancer
|
Mar 17, 2021 |
|
Expert Answers to HCP Questions on CAR T-Cell Therapies in Myeloma and Management of Key Toxicities
|
Mar 12, 2021 |
|
Expert Insights on Highlights From ASH 2020 on Multiple Myeloma
|
Mar 12, 2021 |
|
Expert Insights on Key Data From ASH 2020 on Acute and Chronic Leukemias
|
Feb 26, 2021 |
|
Expert Insight on Key Data From WCLC 2020 in Early-Stage Lung Cancer
|
Feb 24, 2021 |
|
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Argentina
|
Feb 22, 2021 |
|
Expert Insights on Key Data From ASH 2020 on Nonmalignant Hematologic Disorders
|
Feb 10, 2021 |
|
Expert Insights on Key Data From ASH 2020 on Myelodysplastic Syndromes and Myeloproliferative Neoplasms
|
Feb 05, 2021 |
|
Expert Answers to Questions on Contemporary Management of Hemophilia A
|
Feb 04, 2021 |
|
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Italy
|
Feb 04, 2021 |
|
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From the United States
|
Feb 01, 2021 |
|
An Expert Overview of Immunotherapy for Advanced HCC
|
Jan 19, 2021 |
|
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Spain
|
Jan 08, 2021 |
|
Expert Answers to Pathologist Questions on New Biomarkers for Precision Therapy in Lung Cance
|
Dec 28, 2020 |
|
Application of Individualized Treatment for CLL/SLL: Novel Agents, Combinations, and Sequencing Therapy: FAQ
|
Dec 24, 2020 |
|
Practical Insights on Key Data From ESMO 2020 Informing Precision Medicine in NSCLC
|
Dec 21, 2020 |
|
Immunotherapy for Advanced HCC: Experts Answer Clinician Questions
|
Dec 17, 2020 |
|
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From the Netherlands and the United Kingdom
|
Nov 20, 2020 |
|
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From France
|
Nov 19, 2020 |
|
Molecular Classification of Endometrial Carcinoma in the Clinic Today
|
Nov 11, 2020 |
|
Advances in Immunotherapy for Endometrial Cancer
|
Nov 11, 2020 |
|
Biomarkers in Ovarian Cancer: Expert Discussion of Options for First-line Maintenance Therapy
|
Oct 02, 2020 |
|
Developments in Acute Leukemias: Expert Answers to Clinician Questions
|
Oct 02, 2020 |
|
Biomarkers in Ovarian Cancer: Expert Discussion of BRCA Testing and Beyond
|
Oct 02, 2020 |
|
Experts Discuss Evolving State-of-the-Art Management of Patients With HER2-Positive MBC
|
Sep 21, 2020 |
|
The Art of Medicine: Clinical Considerations for Patients With Advanced RCC
|
Sep 21, 2020 |
|
Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 1
|
Sep 17, 2020 |
|
Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 3
|
Sep 17, 2020 |
|
Clinical Considerations for RET Fusion–Positive NSCLC
|
Sep 17, 2020 |
|
Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 2
|
Sep 16, 2020 |
|
CAR T Cell Therapy for Lymphoma, Leukemia, and Myeloma: Experts Answer Clinician Questions
|
Sep 14, 2020 |
|
Practical Application of Immuno-Oncology in RCC: Expert Discussion of Second-line Therapy and Beyond
|
Sep 08, 2020 |
|
FAQ on New Therapeutic Developments in Relapsed/Refractory Multiple Myeloma
|
Sep 03, 2020 |
|
New Advances in Relapsed/Refractory Multiple Myeloma: Frequently Asked Questions on Current and Emerging Treatments
|
Sep 01, 2020 |
|
Practical Application of Immuno-Oncology in RCC: Expert Discussion of Frontline Therapy
|
Aug 31, 2020 |
|
Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma
|
Aug 31, 2020 |
|
MET Exon 14 Mutation–Positive NSCLC: FAQ Part 1
|
Aug 28, 2020 |
|
MET Exon 14 Mutation–Positive NSCLC: FAQ Part 2
|
Aug 28, 2020 |
|
Immunotherapy in SCLC: FAQ on Current Best Practice and Emerging Therapeutic Strategies
|
Aug 27, 2020 |
|
Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: CLL
|
Aug 26, 2020 |
|
Future Treatment Strategies for Acute Myeloid Leukemia—Emerging Targeted Therapy Combinations and Beyond
|
Aug 14, 2020 |
|
Tumor Agnostic TRK Inhibitor Therapy and NTRK Fusion Testing: Experts Answer Clinician Questions
|
Aug 14, 2020 |
|
Improving Outcomes for Patients With CML With TKIs: FAQ Podcast
|
Aug 13, 2020 |
|
Precision Therapy in Lung Cancer: FAQ on Biomarker Testing and Targeted Therapies
|
Aug 10, 2020 |
|
Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types: Answering Clinician Questions
|
Aug 10, 2020 |
|
Precision Therapy in Lung Cancer: FAQ on Biomarkers for Immune Checkpoint Inhibitors
|
Aug 10, 2020 |